Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Sargent

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Diabetes, Obesity & Metabolism|February 28, 2024
Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutideCaroline Swift, Monica Frazer, Noelle N Gronroos, et al.
Advances in Therapy|September 23, 2023
Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral SemaglutideMonica Frazer, Caroline Swift, Noelle N Gronroos, et al.
Journal of Diabetes and Metabolic Disorders|June 27, 2024
Real-world HbA<sub>1c</sub> changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetesMonica Frazer, Caroline Swift, Andrew Sargent, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 9, 2024
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral SemaglutideCaroline Swift, Monica S Frazer, Noelle N Gronroos, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Diabetes, Obesity & Metabolism|February 28, 2024
Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutideCaroline Swift, Monica Frazer, Noelle N Gronroos, et al.
Advances in Therapy|September 23, 2023
Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral SemaglutideMonica Frazer, Caroline Swift, Noelle N Gronroos, et al.
Journal of Diabetes and Metabolic Disorders|June 27, 2024
Real-world HbA<sub>1c</sub> changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetesMonica Frazer, Caroline Swift, Andrew Sargent, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 9, 2024
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral SemaglutideCaroline Swift, Monica S Frazer, Noelle N Gronroos, et al.
Pageof 2